Inclusion Criteria:

- Histologically or cytologically confirmed malignant pleural mesothelioma:

- Measurable disease

- No progressive disease inside or outside of any prior radiation field

- No symptomatic, untreated, or uncontrolled CNS metastases

- Patients with CNS metastases treated with whole brain radiation (WBRT) may be
enrolled after completion of WBRT

- Patients may begin study therapy as early as the next day after completion
of WBRT

- ECOG performance status 0-2

- Life expectancy >= 12 weeks

- ANC >=1,500/mm^3

- Platelet count >= 100,000/mm^3

- WBC >= 3,000/mm^3

- Bilirubin =< 1.5 times upper limit of normal (ULN)

- AST and ALT =< 2.5 times ULN

- Alkaline phosphatase =< 2.5 times ULN

- Creatinine =< 1.5 times ULN or creatinine clearance >= 50 mL/min

- Proteinuria =< 1+ on 2 consecutive dipsticks taken >= 1 week apart

- No condition that impairs ability to swallow and retain study drug tablets including,
but not limited to, any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication

- Requirement for IV alimentation

- Prior surgical procedures affecting absorption

- Active peptic ulcer disease

- No other primary malignancy except for carcinoma in situ of the cervix or
nonmelanomatous skin cancer, unless that prior malignancy was diagnosed and
definitively treated ≥ 5 years ago with no subsequent evidence of recurrence

- Patients with a history of low-grade (Gleason score =< 6) localized prostate cancer
are eligible even if diagnosed within the past 5 years

- No history of allergic reactions attributed to compounds of similar chemical or
biological composition to pazopanib hydrochloride or other agents used in the study

- None of the following concurrent severe and/or uncontrolled medical conditions:

- Serious or nonhealing wound, ulcer, or bone fracture

- Abdominal fistula, diverticulosis, gastrointestinal perforation, or
intra-abdominal abscess within the past 28 days

- Poorly controlled diabetes

- Interstitial pneumonia

- Extensive and symptomatic interstitial fibrosis of the lung

- No cardiovascular illness or complication, including any of the following:

- Any history of cerebrovascular accident within the past 6 months

- History of myocardial infarction (prior electrocardiographic evidence of
myocardial injury)

- History of cardiac arrhythmia (prior electrocardiographic evidence of abnormal
heart rhythm)

- Admission for unstable angina

- Cardiac angioplasty or stenting within the past 12 months

- NYHA class III-IV heart failure

- Asymptomatic NYHA class II heart failure allowed

- QTc prolongation (defined as a QTc interval ≥ 500 msecs) or other significant
electrocardiogram abnormalities

- Venous thrombosis within the past 12 weeks

- No ancillary therapy considered investigational within the past 4 weeks

- No symptomatic, untreated, or uncontrolled seizure disorder

- No uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection or psychiatric illness/social situations that would limit study compliance

- No significant traumatic injury within the past 4 weeks

- No more than 1 prior systemic therapy for malignant pleural mesothelioma

- No major surgery (i.e., laparotomy) or open biopsy within the past 4 weeks

- Insertion of a vascular access device is not considered major or minor surgery

- No minor surgery within the past 2 weeks

- Insertion of a vascular access device is not considered major or minor surgery

- Prior palliative radiotherapy allowed

- No prior palliative radiotherapy to the chest except for a maximum of 3
fractions of radiotherapy for superior vena cava syndrome

- No concurrent therapeutic warfarin

- Low molecular-weight heparin or prophylactic low-dose warfarin allowed

- No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy

- No concurrent medications that act through the CYP450 system

- No concurrent combination antiretroviral therapy for HIV-positive patients

- PT/INR/PTT =< 1.2 times ULN

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective nonhormonal contraception

- No uncontrolled infection

- No uncontrolled blood pressure (BP) (defined as systolic BP > 140 mm Hg and/or
diastolic BP > 90 mm Hg in spite of adequate anti-hypertensive therapy)

- No other severe underlying disease that, in the judgment of the investigator, would
limit study compliance